TSE:TH

Theratechnologies Competitors

C$4.56
-0.28 (-5.79 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.41
Now: C$4.56
C$4.80
50-Day Range
C$3.71
MA: C$4.31
C$4.97
52-Week Range
C$2.30
Now: C$4.56
C$5.34
Volume247,929 shs
Average Volume229,249 shs
Market CapitalizationC$427.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Theratechnologies (TSE:TH) Vs. TRIL, CXR, APS, BU, BLU, and NRI

Should you be buying TH stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Theratechnologies, including Trillium Therapeutics (TRIL), Concordia International (CXR), Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), and Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI).

Theratechnologies (TSE:TH) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Theratechnologies and Trillium Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36
Trillium TherapeuticsC$148,000.008,924.89C$-90,772,073.00C($0.88)-14.55

Theratechnologies has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Theratechnologies and Trillium Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
Trillium Therapeutics0000N/A

Theratechnologies currently has a consensus price target of C$3.75, indicating a potential downside of 17.76%. Trillium Therapeutics has a consensus price target of C$25.00, indicating a potential upside of 95.01%. Given Trillium Therapeutics' higher probable upside, analysts plainly believe Trillium Therapeutics is more favorable than Theratechnologies.

Profitability

This table compares Theratechnologies and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
Trillium TherapeuticsN/AN/AN/A

Summary

Theratechnologies beats Trillium Therapeutics on 4 of the 6 factors compared between the two stocks.

Theratechnologies (TSE:TH) and Concordia International (TSE:CXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Theratechnologies and Concordia International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A

Concordia International has higher revenue and earnings than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Concordia International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
Concordia InternationalN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Theratechnologies and Concordia International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
Concordia International0000N/A

Theratechnologies currently has a consensus target price of C$3.75, suggesting a potential downside of 17.76%.

Summary

Concordia International beats Theratechnologies on 4 of the 4 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Aptose Biosciences and Theratechnologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Theratechnologies02002.00

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 84.90%. Theratechnologies has a consensus target price of C$3.75, indicating a potential downside of 17.76%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Theratechnologies.

Profitability

This table compares Aptose Biosciences and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
TheratechnologiesN/AN/AN/A

Valuation & Earnings

This table compares Aptose Biosciences and Theratechnologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.85)-7.67
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36

Aptose Biosciences has higher earnings, but lower revenue than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Aptose Biosciences beats Theratechnologies on 4 of the 6 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Burcon NutraScience and Theratechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burcon NutraScienceC$12,045.0043,036.02C$107,101.00C$0.004,840.00
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36

Burcon NutraScience has higher earnings, but lower revenue than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Burcon NutraScience and Theratechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burcon NutraScience00103.00
Theratechnologies02002.00

Burcon NutraScience presently has a consensus price target of C$5.00, suggesting a potential upside of 3.31%. Theratechnologies has a consensus price target of C$3.75, suggesting a potential downside of 17.76%. Given Burcon NutraScience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Burcon NutraScience is more favorable than Theratechnologies.

Profitability

This table compares Burcon NutraScience and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burcon NutraScienceN/AN/AN/A
TheratechnologiesN/AN/AN/A

Summary

Burcon NutraScience beats Theratechnologies on 7 of the 8 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for BELLUS Health and Theratechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
Theratechnologies02002.00

Theratechnologies has a consensus target price of C$3.75, suggesting a potential downside of 17.76%. Given Theratechnologies' higher possible upside, analysts clearly believe Theratechnologies is more favorable than BELLUS Health.

Earnings and Valuation

This table compares BELLUS Health and Theratechnologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$15,000.0029,559.16C$-42,145,306.00C($0.54)-10.52
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36

Theratechnologies has higher revenue and earnings than BELLUS Health. Theratechnologies is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BELLUS Health and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
TheratechnologiesN/AN/AN/A

Theratechnologies (TSE:TH) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Theratechnologies and Nuvo Pharmaceuticals Inc. (NRI.TO), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Theratechnologies presently has a consensus target price of C$3.75, indicating a potential downside of 17.76%. Given Theratechnologies' higher probable upside, research analysts plainly believe Theratechnologies is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Theratechnologies and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Earnings & Valuation

This table compares Theratechnologies and Nuvo Pharmaceuticals Inc. (NRI.TO)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.35C$-6,980,844.00C($0.61)-58.33

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than Theratechnologies. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.


Theratechnologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRIL
Trillium Therapeutics
0.9$12.82-1.3%C$1.30 billionC$148,000.00-14.55Gap Down
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
APS
Aptose Biosciences
1.3$6.49-1.8%C$566.20 millionN/A-7.67
BU
Burcon NutraScience
1.2$4.84-1.0%C$518.37 millionC$12,045.004,840.00News Coverage
Gap Down
BLU
BELLUS Health
0.5$5.66-2.8%C$430.85 millionC$15,000.00-10.52Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.76-2.3%C$407.18 millionC$76.09 million-58.33Gap Up
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22News Coverage
MDNA
Medicenna Therapeutics
0.5$5.07-1.2%C$268.21 millionN/A-16.41News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.56-4.5%C$258.17 millionC$52.78 million-1.16
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.49-1.1%C$236.31 millionC$3,000.00-6.04News Coverage
Gap Down
ONC
Oncolytics Biotech
1.2$3.86-2.8%C$209.49 millionN/A-6.89Analyst Report
News Coverage
ATE
Antibe Therapeutics
1.3$4.58-0.4%C$209.33 millionC$9.33 million-5.82
RVX
Resverlogix
0.7$0.87-1.1%C$205.91 millionN/A79.09Upcoming Earnings
News Coverage
Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.51-4.1%C$195.28 millionC$170,000.00-7.84
IPA
ImmunoPrecise Antibodies
0.4$13.58-7.9%C$123.03 millionC$17.18 million-63.46
HBP
Helix BioPharma
0.5$0.88-3.4%C$119.96 millionN/A-16.00Gap Down
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.59-0.0%C$88.79 millionC$81,000.0017.35Gap Up
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.60-1.7%C$65.67 millionC$11.64 million-11.76News Coverage
Gap Down
SBM
Sirona Biochem
0.5$0.35-5.7%C$58.80 millionC$123,870.00-26.92
PMN
ProMIS Neurosciences
0.5$0.17-8.8%C$56.60 millionC$1,787.00-8.50Gap Up
COV
Covalon Technologies
0.6$1.43-0.0%C$37.44 millionC$23.84 million-6.01Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27-3.7%C$34.02 millionC$13.02 million-0.39
IGX
IntelGenx Technologies
0.9$0.60-10.0%C$30.87 millionC$1.54 million-9.23High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.10-10.5%C$21.76 millionC$38,871.000.15High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.78-0.0%C$21.65 millionC$16.14 million23.64Gap Up
CTX
Crescita Therapeutics
0.6$0.84-1.2%C$17.34 millionC$15.64 million420.00News Coverage
KNE
Kane Biotech
0.4$0.16-0.0%C$14.12 millionC$1.34 million-4.57Gap Down
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.10-5.3%C$12.70 millionN/A-4.32Gap Down
NSP
Naturally Splendid Enterprises
0.6$0.06-8.3%C$11.06 millionC$2.03 million-1.40Gap Up
MPH
Medicure
0.7$1.58-1.3%C$10.80 millionC$12.71 million-1.02
BTI
Bioasis Technologies
0.7$0.39-1.3%C$10.16 millionC$4.12 million35.00
HEM
Hemostemix
0.6$0.45-2.2%C$9.07 millionN/A-2.68Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.37-1.4%C$6.94 millionC$5.60 million6.76News Coverage
Gap Down
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$4.00-12.5%C$4.48 millionN/A-1.29High Trading Volume
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$45.95-3.2%C$0.00C$267.59 million50.49News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.